The treatment arm
received palbociclib together with standard of care for this population, fulvestrant, a drug that blocks the hormone receptor via a different mechanism than first - line therapies.
Not exact matches
And Onyx could
receive milestone payments and royalties from
palbociclib, a drug that Pfizer Inc. is studying as a breast cancer treatment.